88 related articles for article (PubMed ID: 22164405)
41. Effect of flutamide androgen-receptor blockade on rat prostatic VIP receptor/effector system.
Carmena MJ; Montalvo L; Solano RM; Clemente C; Román ID; Sánchez-Chapado M; Prieto JC
Ann N Y Acad Sci; 2000; 921():377-80. PubMed ID: 11193859
[No Abstract] [Full Text] [Related]
42. Colorectal cancer cells induce lymphocyte apoptosis by an endothelial monocyte-activating polypeptide-II-dependent mechanism.
Murray JC; Symonds P; Ward W; Huggins M; Tiga A; Rice K; Heng YM; Todd I; Robins RA
J Immunol; 2004 Jan; 172(1):274-81. PubMed ID: 14688335
[TBL] [Abstract][Full Text] [Related]
43. Biological profile of cortexolone 17alpha-propionate (CB-03-01), a new topical and peripherally selective androgen antagonist.
Celasco G; Moro L; Bozzella R; Ferraboschi P; Bartorelli L; Quattrocchi C; Nicoletti F
Arzneimittelforschung; 2004; 54(12):881-6. PubMed ID: 15646372
[TBL] [Abstract][Full Text] [Related]
44. Perturbation of fluid reabsorption in the efferent ducts of the rat by testosterone propionate, 17beta-oestradiol 3-benzoate, flutamide and tamoxifen.
Hansen LA; Clulow J; Jones RC
Int J Androl; 1997 Oct; 20(5):265-73. PubMed ID: 16130270
[TBL] [Abstract][Full Text] [Related]
45. Tumorigenesis disrupts hormonal regulation of tenascin expression in regressing Dunning R 3327 H prostate carcinoma.
Vollmer G; Michna H; Schneider MR
Cancer Lett; 1996 Mar; 101(2):185-92. PubMed ID: 8620468
[TBL] [Abstract][Full Text] [Related]
46. Quantification of antiandrogen effect determined by Lightcycler technology.
Nellemann C; Vinggaard AM; Dalgaard M; Hossaini A; Larsen JJ
Toxicology; 2001 May; 163(1):29-38. PubMed ID: 11376863
[TBL] [Abstract][Full Text] [Related]
47. Antitumor effects of EMAP II against pancreatic cancer through inhibition of fibronectin-dependent proliferation.
Schwarz RE; Awasthi N; Konduri S; Caldwell L; Cafasso D; Schwarz MA
Cancer Biol Ther; 2010 Apr; 9(8):632-9. PubMed ID: 20212356
[TBL] [Abstract][Full Text] [Related]
48. Morphologic and biochemical changes in male rat lung after surgical and pharmacological castration.
Ojeda MS; Gómez NN; Gil E; Scardapane L; Gimenez MS
Braz J Med Biol Res; 2000 Mar; 33(3):279-85. PubMed ID: 10719378
[TBL] [Abstract][Full Text] [Related]
49. [Nucleic acid and protein biosynthesis in the accessory sex organs of rats during blockade of testosterone effect by androgen antagonist 4-nitro-3-trifluoromethylisobutyranilide].
Varga SV; Sinitsyn PV
Probl Endokrinol (Mosk); 1978; 24(1):107-11. PubMed ID: 634940
[TBL] [Abstract][Full Text] [Related]
50. Endoglin inhibition by sodium acetate and flutamide ameliorates cardiac defective G6PD-dependent antioxidant defense in gestational testosterone-exposed rats.
Olatunji LA; Areola ED; Badmus OO
Biomed Pharmacother; 2018 Nov; 107():1641-1647. PubMed ID: 30257382
[TBL] [Abstract][Full Text] [Related]
51. [Anti-androgenic activity of various substituted carboxyanilides].
Varga SV; Reznikov AG; Bal'on IaG; Lozinskiĭ MO; Smirnov VA
Probl Endokrinol (Mosk); 1983; 29(2):67-71. PubMed ID: 6856597
[TBL] [Abstract][Full Text] [Related]
52. Tissue changes in senescent gerbil prostate after hormone deprivation leads to acquisition of androgen insensitivity.
Campos SG; Gonçalves BF; Scarano WR; Corradi LS; Santos FC; Custodio AM; Vilamaior PS; Góes RM; Taboga SR
Int J Exp Pathol; 2010 Oct; 91(5):394-407. PubMed ID: 20353424
[TBL] [Abstract][Full Text] [Related]
53. The OECD program to validate the rat Hershberger bioassay to screen compounds for in vivo androgen and antiandrogen responses. Phase 1: use of a potent agonist and a potent antagonist to test the standardized protocol.
Owens W; Zeiger E; Walker M; Ashby J; Onyon L; Gray LE
Environ Health Perspect; 2006 Aug; 114(8):1259-65. PubMed ID: 16882536
[TBL] [Abstract][Full Text] [Related]
54. Endothelial-monocyte activating polypeptide II disrupts alveolar epithelial type II to type I cell transdifferentiation.
Chen Y; Legan SK; Mahan A; Thornton J; Xu H; Schwarz MA
Respir Res; 2012 Jan; 13(1):1. PubMed ID: 22214516
[TBL] [Abstract][Full Text] [Related]
55. Inhibition of development of both androgen-dependent and androgen-independent pigment cells in scrotal skin dermis of the rat by antiandrogen treatment during fetal growth.
Wilson MJ
Endocrinology; 1983 Jan; 112(1):321-5. PubMed ID: 6847826
[TBL] [Abstract][Full Text] [Related]
56. Endothelial monocyte-activating polypeptide II, a tumor-derived cytokine that plays an important role in inflammation, apoptosis, and angiogenesis.
Berger AC; Tang G; Alexander HR; Libutti SK
J Immunother; 2000; 23(5):519-27. PubMed ID: 11001545
[TBL] [Abstract][Full Text] [Related]
57. Antiandrogenic effect of delta-9-tetrahydrocannabinol in adult castrated rats.
Ghosh SP; Chatterjee TK; Ghosh JJ
J Reprod Fertil; 1981 Jul; 62(2):513-7. PubMed ID: 6166747
[TBL] [Abstract][Full Text] [Related]
58. Endothelial monocyte activating polypeptide II inhibits lung neovascularization and airway epithelial morphogenesis.
Schwarz MA; Zhang F; Gebb S; Starnes V; Warburton D
Mech Dev; 2000 Jul; 95(1-2):123-32. PubMed ID: 10906456
[TBL] [Abstract][Full Text] [Related]
59. A transcriptome approach evaluating effects of neonatal androgen and anti-androgen treatments on regulation of luteal function in sexually mature pigs.
Knapczyk-Stwora K; Costa MC; Gabriel A; Grzesiak M; Hubalewska-Mazgaj M; Witek P; Koziorowski M; Slomczynska M
Anim Reprod Sci; 2020 Jan; 212():106252. PubMed ID: 31864499
[TBL] [Abstract][Full Text] [Related]
60. Effect of two antiandrogens as protectors of prostate and brain in a Huntington's animal model.
Guzman DC; Bratoeff E; Riveros AC; Brizuela NO; Mejia GB; Garcia EH; Olguin HJ; Cruz EG
Anticancer Agents Med Chem; 2014; 14(9):1293-301. PubMed ID: 25323034
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
